FDA Accepts Supplement Application for CRYSVITA (BUROSUMAB-TWZA)
The FDA has accepted a supplemental application for CRYSVITA (BUROSUMAB-TWZA) from Kyowa Kirin.
Therapeutic Area
Therapeutic area intelligence for Hypophosphatemia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.